【摘要】 目的:评价基因重组人生长激素（rhGH）治疗青春期前特发性生长激素缺乏症（IGHD）患儿6个月的疗效和安全性。方法:对49例IGHD患儿进行rhGH治疗,每晚睡前皮下注射0．5IU·kg^-1,每周分5次注射,共26周。评价治疗前后身高、生长速度、身高标准差计数（SDS）等指标。结果:在rhGH治疗期间,46例患儿生长速度由每年（2．5±1．0）cm提高到（11．5±2．5）cm（P＜0．005）。身高SDS由治疗前（-4．2±1．8）增为（-3．7±1．8）。同时患儿13和26周血清胰岛素样生长因子（IGF-1）和IGF结合蛋白（IGFBP,）水平均较治疗前明显升高（P＜0．05）。其体重与骨龄无明显变化。治疗后共有15．7%患儿出现甲状腺功能降低,抗hGH抗体阳性率为21．7%,但所有这些现象均未影响患者体格的线性增长。在治疗期间所有患者肝肾功能、血尿常规和代谢性指标（如血糖和血脂水平）等均保持在正常范围。结论:rhGH是治疗IGHD安全有效的药物。更多还原

【Abstract】 Objectlve:To assess the efficacy and safety of recombinant growth hormone LG Eu- tropin^TMfor children with idiopathic growth hormone deficiency（IGHD）.Methods:49 children with IGHD were subcutaneously injected with Eutropin^TMin a dose of 0.5 IU/kg/week,divided by 5 times,before sleep for 26 weeks.The primary endpoints are to measure the changes of height,growth velocity and mean height SDS pre and post therapy.Results:The mean growth velocity and mean height SDS increased from （2.45±0.97）cm/year,（-4.2±1.8）to（11.5±2.5）cm/year,（-3.7±1.8）,respectively;the p values were P＜0.005.The serum IGF-1 and IGFBP3 levels at the 13 and 26 weeks of the therapy in- creased significantly from the baseline levels.No bone maturation in advance and weight gain were found. 15.7% and 21.7% patients who received Eutropin^TMexperienced hypothyroidism and increment of low titer serum anti-rhGH antibody,respectively,all of which had no an effect on their linear body growth.No ab- normalities in the liver and kidney functions,blood and urinary tests and metabolism index were found. Condusion:This LG rhGH is an effective and safe growth stimulator in children with IGHD.更多还原